Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
You may also be interested in...
A new multinational analysis by ResMed showed that the number of people with sleep apnea is 10 times higher than previous estimates by the World Health Organization, raising the need for developing strategies to raise awareness of the disease and diagnose and treat the disease.
An expert panel at the AdvaMed Digital MedTech Conference discussed the impact of new privacy rights and data protection, in particular CCPA and GDPR, on medtech companies and ways for companies to deal with the challenge of compliance.
The worldwide airway management accessories and sleep apnea management products market is expected to reach $10.3bn by 2022, a CAGR of 7.4%. This market is largely driven by the rising prevalence of age- and obesity-related respiratory disorders, the rising demand for at-home patient care and rapid growth of sleep apnea treatment device sales. The three major players are Philips Healthcare, ResMed and Drive DeVilbiss.